Experience with "AlfaVit Diabetes" used in the treatment of diabetic peripheral polyneuropathy in adolescents

AIM: To evaluate the efficiency of using the vitamin and mineral complex (VMC) AlfaVit Diabetes in the combination therapy of diabetic polyneuropathy (DPNP) in adolescents. /MATERIAL AND METHODS: A study group comprised 30 children with diabetic peripheral polyneuropathy, whose combination therapy included AlfaVit Diabetes as one tablet t.i.d. for 2 months. A comparison group consisted of 20 adolescents with DPNP who did not take the complex. Before and 2 months after the study, the children's state was assessed from the data of a physical examination with mandatory blood pressure and pulse measurements and a neurological study, from carbohydrate (basal glycemia, glycemic variability, glycated hemoglobin) and lipid (total cholesterol and its fractions) metabolic parameters, and from the findings of electromyography (EMG) /RESULTS: Incorporation of the VMC AlfaVit Diabetes into the combination therapy contributed to the ameliorated clinical manifestations of DPNP. There were positive electrophysiological changes, as evidenced by EMG. The VMC AlfaVit Diabetes showed good tolerability and caused no adverse reactions /CONCLUSION: The performed trials have indicated that it is expedient to use the VMC AlfaVit Diabetes in adolescents with type 1 diabetes mellitus and DPNP.

type 1 diabetes mellitus, diabetic peripheral polyneuropathy, adolescents, AlfaVit Diabetes